Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

ASTX727 (decitabine/cedazuridine)

Stage Phase 1

Sponsor Massachusetts General Hospital

Modality small molecule

Class DNMT inhibitor

Target DNMT1 (hypomethylating)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/api/v2/studies?query.cond=glioma&query.term=IDH

ClinicalTrials.gov API v2: IDH-mutant glioma interventional records plus 34 individual records, retrieved 11.07.2026 (registry fields as entered by sponsors)

Brief source I16

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03922555

Phase I Trial of ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT03922555

Registry NCT03922555

Phase Phase 1

Status Recruiting

Enrollment 18

Start 2019-07-12

Primary completion 2027-01-01

Study completion 2028-08-01

Catalyst Primary completion. 01.01.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.